Although survival has improved in recent years, the prognosis of patients with advanced pancreatic ductal adenocarcinoma (PDAC) remains poor. Despite substantial differences in anatomy, physiology, genetics, and metabolism, the overwhelming majority of preclinical testing relies on transgenic mice. Hence, while mice have allowed for tremendous advances in cancer biology, they have been a poor predictor of drug performance/toxicity in the clinic. Given the greater similarity of sus scrofa pigs to humans, we engineered transgenic sus scrofa expressing a LSL-KRAS G12D -TP53 R167H cassette. By applying Adeno-Cre to pancreatic duct cells in vitro, cells self-immortalized and established tumors in immunocompromised mice. When Adeno-Cre was administered to the main pancreatic duct in vivo, pigs developed extensive PDAC at the injection site hallmarked by excessive proliferation and desmoplastic stroma. This serves as the first large animal model of pancreatic carcinogenesis, and may allow for insight into new avenues of translational research not before possible in rodents.
The porcine pancreas is far more human-like than that of rodents, with comparable anatomical orientation and localization 9 . For instance, pig pancreata generally exhibit three distinct lobes, with the duodenal lobe corresponding to the head of the human pancreas, the connecting lobe being analogous to the uncinate process, and the splenic lobe corresponding to the tail/body of the pancreas 9 . In light of these many similarities, modeling pancreatic cancer in pigs would provide the opportunity to conduct surgical and radiologic studies never before possible, and may offer additional insight into disease pathogenesis due to the size and composition of the gland.
Currently, the most widely used mouse model of pancreatic cancer consists of concurrent KRAS G12D and TP53 172H mutations targeted to the exocrine pancreas under the Pdx-1 promoter 10 . This model (KPC) has been used extensively and is considered a gold standard within the field. We sought to generate a similar histoype in sus scrofa pigs to provide a more physiologically and anatomically relevant model. We first generated pigs harboring analogous KRAS G12D and TP53 R167H mutations, which are observed in approximately 95% and 50% of human PDAC patients respectively 11, 12 . After demonstrating the ability of these transgenes to induce adenocarcinomatous transformation of pig duct cells ex vivo, we administered an Adenoviral Cre Recombinase (Adeno-Cre) to the pig pancreas in vivo. Following refinement of the delivery system, these mutations successfully induced pancreatic neoplasms and cancer in the pig, providing the first documented large animal model of pancreatic carcinoma.
Materials and Methods
Transgenesis. LSL-KRAS G12D -TP53 R167H pigs were generated as previously described 13 . Pigs and In Vivo Imaging. All animal procedures were approved by the University of Illinois Institutional Animal Care and Use Committee. All pigs used were of the LSL-KRAS G12D -TP53 R167H transgenic line. LSL-KRAS G12D -TP53 R167H pigs were dosed with 4 × 10 9 PFU of Ad5CMVCre-eGFP (Adeno-Cre), either directly into the body of the pancreas or into the pancreatic duct pushed toward the pancreas. For all cases the pancreas was accessed surgically through a ventral midline incision. Anesthesia was induced with TKX (Telazol, Ketamine, Xylazine), intubated and maintained in a surgical plane of anesthesia with Isoflurane.
Following recovery, all animals were monitored for general health, weight and periodic blood chemistry evaluation. For euthanasia, each animal was sedated and euthanized with sodium pentobarbital overdose (Fatal plus 10 cc/100 lbs.). All animals underwent gross and histopathologic evaluation. Tissues were then collected and subject to gross and histopathologic analysis.
For in vivo imaging, animals were sedated as described previously and 120 ml of the contrast agent Iohexal (Omnipaque) was delivered intravenously, allowing for visualization of potential pathologies by contrast computed tomography (CT). Scans were limited to the cranial abdomen.
Cell Culture. The pancreas from a two-month old female pig was collected and immediately cut into 1 mm 3 pieces in ice cold DMEM/F12 media with 20% animal serum complex, penicillin (100 units/mL), and streptomycin (100 μg/mL). Tissue was transferred to 50 ml conical tubes and washed with cold media and transferred to a sterile hood. Tissues were washed again and incubated with Collagenase Ia (1 mg/ml) and 0.25 mg/ml of trypsin inhibitor for five minutes at 37 °C. The Collagenase reaction was quenched with PBS with 20% animal serum complex and the cells washed. The reaction was similarly quenched with PBS with 20% animal serum complex and the cells washed in fresh culture media with 20% heat-inactivated fetal bovine serum (FBS), penicillin (100 units/mL), and streptomycin (100 μg/mL). The cells were then seeded on six well plates and allowed to adhere. Once the cells were seeded, they were infected with Adeno-Cre at a 200 to 500 MOI. The media was changed after six hours and cells maintained at 37 °C with 5% CO2.
Mice. 5 × 10 6 PORC1 cells suspended in100 μl of Matrigel, (BD Biosciences, San Diego, CA, USA) and injected subcutaneously into 3 SCID mice (NOD.CB17-Prkdcscid/ JAX, Bar Harbor, ME, USA). Tumor growth data was monitored for up to 100 days. SQ tumors were routinely measured and overall health was assessed by weight and visual inspection. Mice were sacrificed by cervical dislocation, and tissues collected and subject to histopathology. All animal procedures were approved by the University of Illinois Institutional Animal Care and Use Committee.
RT-PCR.
RNA was extracted using Trizol (Fischer-Scientific, Waltham, MA). Quantity/quality was evaluated by spectrophotometer (Nanogen Inc, San Diego, CA) and integrity confirmed via gel electrophoresis. cDNA was then synthesized using the High-Capacity cDNA Reverse Transcription Kit per manufacturer specifications (Fischer-Scientific, Waltham, MA) and rtPCR was conducted with SYBR Green and commercially available TP53 R167H and GAPDH primers (Fischer-Scientific, Waltham, MA). CAG-F: 5′-TCATATGCCAAGTACGCCCC-3′; CAG-R: 5′-CCCCATCGCTGCACAAAATA-3′; TP53-F: 5′-TGGCTC TCCTCAAGCGTATT-3′; TP53-R: 5′-ATTTTCATCCAGCCAGTTCG-3′. Bands displayed were run as shown and without modification.
Histology, immunohistochemistry, and immunofluorescence/immunocytochemistry.
LSL-KRAS G12D -TP53 R167H pigs or were euthanized and subjected to pathological examination the pancreas, small intestine, liver, bile duct, lymph nodes, spleen, omenteum, colon, thyroid, lung, heart, kindeys, diaphragm, esophagus, bladder, and stomach. Similarly, mice were sacrificed via cervical dislocation and xenograft tumors collected. Tissues were fixed in 10% formalin, paraffin-embedded, and sections at 4 μm interval were cut from each tissue, and stained with H&E, trichrome (Sigma Aldrich, St. Louis, MO), or via immunohistochemistry (IHC)/ immunofluorescence (IF).
For IHC, slides were deparaffinized and heated in a pressure cooker using DAKO retrieval buffer (DAKO, Carpinteria, CA). Endogenous peroxidases were quenched in DAKO peroxidase block for 20 min. Tissues were blocked with 0.5% BSA in PBS for 30 min and exposed a primary antibodies against RAS G12D (NewEast Biosciences, King of Prussia, PA), PCNA (Santa Cruz, Santa Cruz, CA), αSMA, Synaptophysin, Pancreatic SCIeNTIfIC REPORTS | (2018) 8:12548 | DOI:10.1038/s41598-018-30916-6 amylase (abcam, Cambridge, MA), Vimentin, E-Cadherin, mutant P53, and pERK (Cell Signaling, Danvers, MA) at 1:50-1:400 overnight at 4 °C. Slides were developed using an HRP-conjugated secondary antibody followed by DAB substrate/buffer (DAKO).
For IF, slides were deparaffinized and heated in a pressure cooker using DAKO retrieval buffer (DAKO, Carpinteria, CA). Endogenous peroxidases were quenched in DAKO peroxidase block for 20 min. Tissues were blocked with 0.5% BSA in PBS for 30 min and exposed a primary antibodies against CK19 (University of Iowa Hybridoma Bank, Iowa City, IA), pPancreatic amylase, αSMA, PCNA, (Santa Cruz), Vimentin, or pERK (Cell Signaling) at 1:100 overnight at 4 °C. Slides were visualized using an Alexaflour-488 or 594 conjugated secondary (abcam).
For cultured cells, cells were grown on chamber slides and fixed with ice-cold methanol at −20 °C for 10 minutes. Cells were blocked for 1 hour at room temperature with 0.5% BSA in PBS, and incubated with primary antibodies against CK19 (University of Iowa Hybridoma Bank), E-Cadherin, pERK, (Cell Signaling) or PCNA (Santa Cruz) at 1:50-100 overnight at 4 °C. Slides were visualized using an Alexaflour-488 or 594 conjugated secondary antibody (abcam).
Western blot and immunoprecipitation/RBD Assay. Cell or tissue lysates were lysed in 4% SDS buffer followed by needle homogenization. Equal amounts of protein (15-40 μg) were mixed with loading dye, boiled for 8 min, separated on a denaturing SDS-PAGE gel and transferred to a PVDF membrane. The membrane was blocked in 5% milk/TBS/0.1% Tween for 1 h and incubated with antibodies against pERK, ERK, Vimentin, (Cell Signaling, Danvers, MA, USA), αSMA (abcam), β-Actin (Santa Cruz Biotech, Santa Cruz, CA, USA). The membrane was washed with TBS-0.1% Tween and then incubated with HRP conjugated secondary antibody (Santa Cruz Biotech) at room temperature for 1 h and rewashed. Protein bands were visualized by an enhanced chemiluminiscence method (Thermo, Waltham, MA, USA) and resolved digitally per the manufacturer's specifications. For RAS activation assay, a standard kit was purchased and used per manufacturer specification (Thermo). All experiments were performed in triplicate unless otherwise specified.
Flow cytometry. Cultured pancreas cells were seeded into a round-bottom 96-well plate, washed in PBS, and stained with anti-RAS G12D antibody (New East Biosciences) 1:100 in PBS with 1% BSA over ice for 20 minutes. Cells were analyzed with a BD Fortessa. All flow plots correspond to size appropriate single cells and are representative of 100,000 events unless otherwise stated.
Study approval.
All experiments involving the use of mice were performed following protocols approved by the Institutional Animal Care and Use Committee at the University of Illinois. Patient slides and information was obtained in a de-identified fashion from the Northwestern University Pathcore, following local IRB approval. All patients offered informed consent for study participation. All methods were performed in accordance with the relevant guidelines and regulations
Results

KRAS and TP53 mutations induce metastatic behavior in porcine pancreatic duct cells.
To assess the viability of loxp-STOP-loxp (LSL)-KRAS G12D -TP53 R167H pigs as a potential model of PDAC, we first compared the microscopic anatomy of the human, murine, and porcine pancreas. Despite the described structural differences, we found that the gland histology was remarkably similar among the three species (Fig. S1 ). In light of these similarities, we next euthanized a 2-month-old female LSL-KRAS G12D -TP53 R167H pig and removed the pancreas gland. We then extracted and digested the main pancreatic duct to isolate duct cells, and infected them with 1 × 10 6 units of Adeno-Cre in vitro. Cells displayed normal ductal morphology and negligible proliferation 24 hours after transduction. However, 7 days following transduction, LSL-KRAS G12D -TP53 R167H expressing duct cells had self-immortalized, now displaying spindle shaped morphology consistent with malignant transformation ( Fig. 1A) . Additionally, transduced cells also demonstrated robust expression of the TP53 R167H transcript/ protein (Figs 1B,C and S2A), as well as the mutant RAS G12D protein as determined by immunocytochemistry and verified by both western blot and flow cytometry (Figs 1D,E and S2A). These transformed cells, named Porcine Carcinoma 1 (PORC1), strongly expressed E-cadherin and CK19, affirming their ductal lineage. Consistent with a tumorigenic phenotype, PORC1 cells also displayed increased RAS activation, as well as strong expression of the KRAS effector pERK1/2 and proliferation surrogate PCNA (Figs 1F and S2B).
We next injected 5-10 × 10 6 PORC1 cells either subcutaneously (SQ) or intraperitoneally (IP) into SCID mice (N = 7 per group). Mice with SQ injection developed large masses under the skin at each injection site ( Fig. S3A ), while mice with IP injection developed several large focal plaques on the abdominal viscera that were easily palpable ( Fig. 1G ). SQ tumors were routinely measured and overall health was assessed by weight ( Fig. S3B ). Like human PDAC, these tumors had a dense, cellular stroma, with cancer cells staining for E-cadherin, indicating an epithelial origin. These epithelial cells were distinct from the fibrous component, which was evaluated by Masson's Trichrome staining. Furthermore, like the PORC1 cells in vitro, xenograft tumors were highly positive for CK19, affirming a ductal lineage and expressed mutant RAS G12D . Also consistent human PDAC tumors, the stroma had strong expression of αSMA, a marker of pancreatic stellate cells (Figs 1G and S3A ).
Restriction of Adeno-Cre to the Main Pancreatic Duct Leads to a Predominantly Pancreatic Ductal
Adenocarcinoma Histotype. Given the sufficiency of KRAS G12D and TP53 R167H mutations to transform pancreatic duct cells in vitro, we initiated autochthonous porcine pancreatic tumor formation in vivo. Our first attempts of intraparenchymal delivery of Adeno-Cre resulted in a mixed histotype of leiomyosarcoma and duct-derived neoplasms akin to those seen in human patients (N = 3, Figs S4 and S5, and Supplementary Results). Given the presence of clinically relevant pancreatic neoplasms, we next attempted to recreate the described duct-derived pancreas histotype pancreas histotype while avoiding the leiomyosarcoma phenotype observed in our initial experiments. Therefore, we repeated the above experiment focusing on transformation of ductal epithelial cells rather than mesenchyme by surgically injecting 4 × 10 9 units of Adeno-Cre directly into the main pancreatic duct.
One year following injection, there were no overt signs of illness or pancreatic insufficiency as observed in the previous cohort. Similarly, contrast-enhanced computed tomography (CT) showed no evidence of gross tumor formation at the injection site or near the pancreas. Additionally, the hepatobilliary tract, spleen, liver, and regional lymph nodes appeared normal with no sign of lesions. The stomach was moderately filled with gas and fluid with a mild amount of hyper-attenuating material in the dependent region of the fundus, though there was no clear sign of overt abnormality (Fig. S6A ). Furthermore, upon euthanasia, the pancreas displayed no overt signs of sarcoma and had three distinct lobes. However, on dissection, the main pancreatic duct was large and firm with several large, nodular tumors with a pronounced fibrous component at the site of cannulation (Fig. S6B) .
Tumors were then fixed and sectioned, and compared directly to human PDAC samples. Upon histological evaluation of several geographically separate areas, porcine tumors consistently displayed morphological features consistent with human PDAC ( Fig. 2A,B ). In addition to having no evidence of sarcoma or smooth muscle abnormality, there were several areas consisting of lumenal masses with considerable cellular atypia and invasion through the basement membrane (Fig. 2B) . Like human PDAC, these lesions were accompanied by a dense and desmoplastic tumor stroma rich with leukocytes ( Fig. 2A,B) .
Consistent with a PDAC phenotype, porcine tumor sections were positive for both E-cadherin and CK19 (Fig. 2C ). Though the predominant histotype was derived from exocrine pancreas, there were distinct and geographically separate areas that appeared to have a phenotype more similar to pancreatic neuroendocrine tumors (PNET). We therefore compared these areas directly to human PNET sections, and found that they shared several histological features, including a less pronounced desmoplastic tumor stroma ( Fig. S7A,B) and stained positive for the neuroendocrine marker Synaptophysin (Fig. S7C ).
LSL-KRAS G12D -TP53 R167H -Induced PDAC Displays Excessive Proliferation. To assess changes in
KRAS activity, we first performed a RAS activation assay using control and tumor tissues. As expected, in PDAC tissues, KRAS protein had increased GTP binding ratio compared to control tissues, and exhibited robust expression of KRAS G12D and P53 R172H proteins. These were accompanied by enhanced ERK activation as determined by western blotting (Fig. S8) and confirmed by immunohistochemistry, localizing pERK to areas suspect for PDAC ( Figs 3A and S9A ). These areas also stained strongly for PCNA, a surrogate marker of cell proliferation (Figs 3B and S9B) , whereas adjacent normal tissue had little to no PCNA staining (data not shown). To affirm that these proliferating regions were indeed those previously identified as PDAC, we dual-stained tissues for both the ductal marker CK19 and PCNA. Regions proliferating most strongly were also CK19 positive, indicative of PDAC (Fig. 3C) . Similarly, areas suspect for PNET also displayed robust ERK activation as well as PCNA staining, further suggesting the presence of endocrine-derived neoplasms (Fig. S7D ).
Porcine PDAC Develops a Desmoplastic Stroma Analogous to Human Patients.
As the pancreatic cancer stroma is not only a near uniform histological feature but also a key component of disease progression and chemo-resistance 14, 15 , we analyzed the tumor microenvironment of both human and porcine PDAC sections. As expected, all human PDAC samples examined had a dense, desmoplastic tumor stroma that stained positive with Masson's Trichrome (Fig. 4A) . Porcine tumors were similarly desmoplastic with increased Collagen IA expression ( Fig. S8 ) and also stained positive with Masson's Trichrome (Fig. 4B) . Similarly, expression of the mesenchymal marker Vimentin was increased ( Fig. S8) and localized exclusively to the tumor stroma ( Fig. 4C ). As pancreatic stellate cells are considered the critical mediator of tumor-associated fibrosis 16 , we next assessed tumor sections for expression of αSMA, which was also localized to the stroma and was associated with areas of CK19-positive PDAC (Fig. 4D ).
Discussion
The poor survival associated with pancreatic cancer stems largely from the fact that most patients initially present with highly advanced disease. As most of these patients are not candidates for surgical intervention and there is no effective pharmacological therapy, there is an urgent need to develop new therapeutic approaches. To do so, investigators have relied almost exclusively on genetically engineered mouse models. For example, the Pdx promoter has been used to drive Cre expression in the progenitor cells of the pancreas, which when crossed to a loxp-STOP-loxp (LSL) cassette resulted in a faithful recapitulation of the more common PanIN histotype 17 . Combining this model with an LSL-TP53 R172H cassette resulted in a metastatic model of PDAC with histology closely resembling that observed in human patients 10 . These KPC mice have been favored by a number of investigators for this reason, and have provided a reliable and accurate model of human PDAC for over a decade. However, despite the success of the KPC mice, there are still the inherent limitations of the mouse anatomy and physiology that must be considered.
Importantly, the mouse pancreas has significant micro and macroscopic differences to that of humans. The human pancreas is a firm organ that is segmented into three borderless, yet distinct parts: the head, body, and tail 18 . In contrast, the mouse pancreas is soft and diffuse with three poorly defined lobes 19 . There are also pronounced differences of the ductal tree between the two species. In humans, the pancreatic acini are the predominant exocrine cell type and are organized into lobules that secrete to a small, intercalated duct. These intercalated ducts drain to a larger, interlobular duct that join to form the large, main pancreatic duct which empties to the duodenum adjacent to the common bile duct 18 . In mice, however, a large interlobular duct drains the three respective lobes. Ducts from the splenic and gastric lobes then merge with the common bile duct far more proximal to the duodenum than in humans 18 .
In addition to these structural variances, there are several genetic factors that account for further differences in mouse and human carcinogenesis. Despite sharing a similar number of protein coding genes 20 , the mouse genome is substantially different from that of humans. Though much is shared, there is significant variance in transcriptional regulation and chromatin organization between the two species 21 . This is particularly true of genes involved in the inflammatory response 22 , indicating that mice may have limited utility in inflammation-associated diseases such as pancreatic cancer 23 . Another notable disparity between mouse and human genetics is the failure of mutations in Cystic Fibrosis Transmembrane Regulator (CFTR) gene to induce significant pancreatic disease as it does in humans 24 . These issues were resolved by modeling the disease in pigs, which lead to a more faithful recapitulation of the disease pathology and destruction of the exocrine pancreas 25, 26 . We therefore attempted to recreate the success of the KPC model in the more genetically and anatomically similar sus scrofa domestic pig, in order to provide a more clinically relevant model of PDAC.
Initial attempts at intrapancreatic delivery of Adeno-Cre resulted in a mixed histotype. While the pigs developed PanIN lesions within 16 days, we also observed lethal smooth muscle derived leiomyosarcoma, likely due to the malignant transformation of vascular smooth muscle infected with Adeno-Cre. These two cancer types generally do not present simultaneously. Therefore, it was necessary to refine our approach in order to generate a clinically relevant PDAC histotype. By restricting the delivery of our Cre using an intraductal injection, we were able to induce locally invasive PDAC without the presence of an underlying sarcoma. Interestingly, this approach also resulted in a somewhat mixed histotype, this time consisting of PDAC as well as rare and geographically isolated regions of PNET. Mixed tumors and mixed adenoneuroendocine carcinomas (MANEC) of the gastrointestinal tract and pancreas have been well described by our group as well as many others 27 . They are commonly aggressive tumors most frequently occurring in the head of the gland and management is often a combination of surgery and platinum-based chemotherapy. At the present time, this may be the most appropriate category for tumors induced by LSL-KRAS G12D -TP53 R167H pigs, though PDAC appeared to predominate, particularly in sections closest to the main pancreatic duct. Therefore, future work will employ improved exocrine targeting to exclude the neuroendocrine compartment.
Based on the size and anatomy of the pig, this model may allow for insight into surgical and interventional radiology techniques never before possible in rodents. Pigs and humans also have largely analogous Cytochrome P450 enzymes, allowing for better pre-clinical evaluation of drug metabolism and therapy 28 . Additionally, given the profound similarity between human and pig immune systems, these LSL-KRAS G12D -TP53 R167H pigs may provide an improved platform for preclinical immunotherapy. Given these advantages, several porcine models of cancer are emerging. These include a mutant APC porcine model of familial adenomatous polyposis (FAP), a heterozygous TP53 knockout model of spontaneous osteosarcomas, and a chemically induced hepatocellular carcinoma (HCC) model 29 . Similarly, our inducible LSL-KRAS G12D -TP53 R167H model has successfully generated soft tissue sarcomas and HCC 13, 29, 30 .
By demonstrating sufficiency of the LSL-KRAS G12D -TP53 R167H pig to model a human-like pancreatic carcinoma both in vitro and in vivo (Summarized in Fig. 5 ), we substantiate the pig as a more physiologically relevant platform in which to model the two predominant pancreatic cancer histotypes, allowing for novel research approaches and bridging the gap from bench to bedside. 
